Renin overexpression in rats leads to diastolic dysfunction through increased titin-based stiffness via hyperphosphorylation of the PEVK domain, providing a potential in vivo model for HFpEF.
Answers are grounded in this paper and cite their sources.
Hypertension effects in mRen2 rats should not change practice; leaves open mechanistic insights for human HF.
Hypertension is a major risk factor for heart failure (HF). We investigated the influence of hypertension on cardiac contraction and relaxation in transgenic renin overexpressing rats (carrying mouse Ren‐2 renin gene, mRen2, n=6). Blood pressure (BP) was measured by tail‐cuff method, echocardiography was used to characterize cardiac contractility, cellular force measurements and biochemical assays were applied to reveal molecular mechanisms. Sprague‐Dawley (SD) rats (n=6) were used as control. Systolic BP was elevated in mRen2 rats (235.11±5.32 vs. 127.03±7.56 mmHg in SD, P<0.05), resulting in increased left ventricular (LV) weight/body weight ratio (4.05±0.09 vs. 2.77±0.08 mg/g in SD, P<0.05). No effects of transgenic renin expression on systolic parameters, such as LV ejection fraction (EF, 68.50±2.09 vs. 70.17±1.45 % in SD), maximal Ca 2+ ‐activated force (25.89±0.99 vs. 29.05±2.80 kN/m2 in SD) and Ca 2+ ‐sensitivity of force production (pCa50, 5.83±0.01 vs. 5.87±0.05 in SD) were found. In contrast, pronounced diastolic dysfunction (DD) was observed in mRen2 rats: ratio of peak early and late LV diastolic filling (E/A) was lower (1.14±0.04 vs. 1.87±0.08, P<0.05), LV isovolumetric relaxation time was longer (43.85±0.89 vs. 28.55±1.33 ms, P<0.05) and cardiomyocyte passive stiffness was higher (1.74±0.06 vs. 1.28±0.18 kN/m2, P<0.05), compared to SD, respectively. Finally, hyperphosphorylation of titin at Ser‐12742 within the PEVK domain (P<0.05) proposed a molecular mechanism for DD. Our data suggest a link between the activation of renin‐angiotensin‐aldosterone system and increased titin‐based stiffness through phosphorylation of titin's PEVK element, contributing to DD. Accordingly, mRen2 rat might provide an in vivo model for HF with preserved EF (HFpEF). Support or Funding Information This work was supported by a European Union FP7 grant (MEDIA: metabolic road to diastolic heart failure) and by the Hungarian Scientific Research Fund (K116940 and K109083).
No takes yet. Share an insight, caveat, or question.
Csípő et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: